Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCNO | P22674 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207223 | 0.76 | CHKA (0.56) | CHKATDP1L3MBTL1HRH3 | |
| SCHEMBL30775404 | 0.76 | SORD (0.56) | SORDCHKAGPR119DRD4GSK3B | |
| SCHEMBL4453478 | 0.76 | SORD (0.56) | SORDCHKAGPR119DRD4GSK3B | |
| SCHEMBL3116626 | 0.76 | PLD1 (0.46) | SORD | |
| SCHEMBL209842 | 0.75 | SORD (0.54) | SORDCHKAGPR119DRD4GSK3B | |
| SCHEMBL209844 | 0.75 | SORD (0.54) | SORDCHKAGPR119DRD4GSK3B | |
| SCHEMBL29611181 | 0.75 | SORD (0.54) | SORDCHKAGPR119DRD4GSK3B | |
| SCHEMBL2646639 | 0.72 | SORD (0.40) | SORDGPR119L3MBTL1 | |
| SCHEMBL15659725 | 0.71 | PLD1 (0.38) | SORDRPS6KA5HSP90AA1GPR119DRD4 | |
| SCHEMBL9767811 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | SORD 2639/4885RPS6KA5 245/4885CHKA 467/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SORD 2639/4885RPS6KA5 245/4885CHKA 467/4885 |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SORD 2639/4885RPS6KA5 245/4885CHKA 467/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SORD 2639/4885RPS6KA5 245/4885CHKA 467/4885 |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | SORD 2639/4885RPS6KA5 245/4885CHKA 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.